Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) IL-2 in patients with AJCC stage IV melanoma

8037 Background: Previous biochemotherapy (BCT) regimens for metastatic melanoma have utilized lower doses of IL-2 and multiple chemotherapeutic agents, adding to toxicity, but not to efficacy. Met...